scholarly journals Motivar el aprendizaje utilizando nuevas tecnologías: Monitorización continua de glucosa - [Motivate learning using new technologies: Continuous glucose monitoring]

2021 ◽  
Author(s):  
E. Obrador ◽  
J.M. Estrela ◽  
S.L. Vallés ◽  
B. Pineda ◽  
V.M. Víctor
Keyword(s):  
Continuous Glucose Monitoring ◽  
New Technologies ◽  
Glucose Monitoring ◽  
Nuevas Tecnologías ◽  
Motivate Learning

scholarly journals Continuous glucose monitoring: review of promising technologies

2019 ◽  
Vol 252 ◽  
pp. 02012
Author(s):  
Monika Klimek ◽  
Tytus Tulwin
Keyword(s):  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
New Technologies ◽  
Glucose Monitoring ◽  
Flash Glucose Monitoring ◽  
Uncontrolled Diabetes ◽  
Monitoring Technologies

Despite the progress we have made in the management of diabetes it is still incurable and aggravating disease affecting all domains of quality of life. Uncontrolled diabetes associated with hyperglycemia leads to serious microvascular and macrovascular long-term complications. The proper long-term glycemic control is a key strategy for preventing the development or slowing the progression of diabetes complications, thus there is a crucial role of new technologies in the diabetes care. New technologies in diabetology are developing dynamically in recent years and therefore this is a topical issue. In this paper we describe current and developing continuous glucose monitoring technologies and their usefulness in promoting optimal glycemic control, influence on personalized diabetes managements and the functioning of patients. Moreover we review knowledge about flash glucose monitoring and close-loop system. This review examines studies published before 31st August 2018.

scholarly journals Use of new technologies in pregnancy

2019 ◽  
Vol 22 (3) ◽  
pp. 146
Author(s):  
Ragusa, I.
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Control ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
New Technologies ◽  
Glucose Monitoring ◽  
Subcutaneous Insulin ◽  
Diabetes In Pregnancy ◽  
Fetal Outcomes ◽  
In Pregnancy

Diabetes in pregnancy is associated with an increased risk of maternal and neonatal complications. Several trials have showed that adequate pregnancy planning and optimal glucose control are essential to reduce the risk of fetal malformations and to improve maternal-fetal outcomes. In clinical practice it’s hard to reach an optimal glucose control in pregnancy. Thus, the new technologies designed to assist patient with diabetes (Continuous subcutaneous insulin infusion and/or Continuous Glucose Monitoring) are widely used during pregnancy planning and management. This article discusses the use of new technologies in the management of diabetes during pregnancy and their effects on glicemic control and maternal-fetal outcomes KEY WORDS diabetes in pregnancy; continuous subcutaneous insulin infusion; continuous glucose monitoring; efficacy; safety

scholarly journals Level of Digitalization in Germany: Results of the Diabetes Digitalization and Technology (D.U.T) Report 2020

2020 ◽  
pp. 193229682096555
Author(s):  
Timm Roos ◽  
Sabine Hochstadt ◽  
Winfried Keuthage ◽  
Jens Kröger ◽  
Andreas Lueg ◽  
...  
Keyword(s):  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Positive Attitude ◽  
Online Survey ◽  
New Technologies ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Continuous Glucose Monitoring System ◽  
Current Status ◽  
Younger Age

Background: New diagnostic and therapeutic technologies are increasingly changing the treatment of people with diabetes (PWD), along with increased usage of digital tools. To date, however, there is little data to which level and how diabetologists and PWD implement digitalization. Also, not much is known about the view of diabetologists on the current status and future developments in this respect. Method: In an online survey, diabetologists working in clinics and practices across Germany provided responses regarding their view on digitalization and the adoption of new technologies in diabetology to 56 questions. These comments reflect the opinion of several experts about the current importance and use of specific digital/technological topics. Results: Overall, 326 diabetologists took part in the survey. They reported a positive attitude (75.8%) toward new technologies and digitalization, and they see more advantages rather than disadvantages. Younger age of the diabetologists was significantly associated with a more positive attitude ( r = −0.176; P < .01), and there was no gender effect ( P = .738). On average, in each practice, 5.5% of PWD are using an insulin pump for therapy, 4.8% a real-time continuous glucose monitoring system, 16.9% an intermittent scanning continuous glucose monitoring system, and 0.3% an automated insulin delivery (AID) system. With respect to digitalization, the three most important current topics are software for glucose data analysis (average rank on a scale from one to six, with one being the most important: 2.4), compatibility with other systems (2.9), and AID systems (3.8)). Conclusions: This survey, which is going to be repeated annually, showed that the diabetologists who participated predominantly have a positive attitude toward new technologies and digital applications and were aware of the associated advantages. However, perceived disadvantages need to be addressed to enable wider adoption of new technologies and digital solutions.

scholarly journals Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial

2018 ◽  
Vol 38 (8) ◽  
pp. 942-953 ◽  
Author(s):  
Wen Wan ◽  
M. Reza Skandari ◽  
Alexa Minc ◽  
Aviva G. Nathan ◽  
Parmida Zarei ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cost Effectiveness ◽  
Continuous Glucose Monitoring ◽  
New Technologies ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Second Phase ◽  
Clinical Effects ◽  
Life Years

Background. The economic impact of both continuous glucose monitoring (CGM) and insulin pumps (continuous subcutaneous insulin infusion [CSII]) in type 1 diabetes (T1D) have been evaluated separately. However, the cost-effectiveness of adding CSII to existing CGM users has not yet been assessed. Objective. The aim of this study was to evaluate the societal cost-effectiveness of CSII versus continuing multiple daily injections (MDI) in adults with T1D already using CGM. Methods. In the second phase of the DIAMOND trial, 75 adults using CGM were randomized to either CGM+CSII or CGM+MDI (control) and surveyed at baseline and 28 weeks. We performed within-trial and lifetime cost-effectiveness analyses (CEAs) and estimated lifetime costs and quality-adjusted life-years (QALYs) via a modified Sheffield T1D model. Results. Within the trial, the CGM+CSII group had a significant reduction in quality of life from baseline (−0.02 ± 0.05 difference in difference [DiD]) compared with controls. Total per-person 28-week costs were $8,272 (CGM+CSII) versus $5,623 (CGM+MDI); the difference in costs was primarily attributable to pump use ($2,644). Pump users reduced insulin intake (−12.8 units DiD) but increased the use of daily number of test strips (+1.2 DiD). Pump users also increased time with glucose in range of 70 to 180 mg/dL but had a higher HbA1c (+0.13 DiD) and more nonsevere hypoglycemic events. In the lifetime CEA, CGM+CSII would increase total costs by $112,045 DiD, decrease QALYs by 0.71, and decrease life expectancy by 0.48 years. Conclusions. Based on this single trial, initiating an insulin pump in adults with T1D already using CGM was associated with higher costs and reduced quality of life. Additional evidence regarding the clinical effects of adopting combinations of new technologies from trials and real-world populations is needed to confirm these findings.

scholarly journals Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?

2020 ◽  
Vol 1 (5) ◽  
pp. 314-330
Author(s):  
Erika Pedone ◽  
Andrea Laurenzi ◽  
Agnese Allora ◽  
Andrea Mario Bolla ◽  
Amelia Caretto
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Continuous Glucose Monitoring ◽  
New Technologies ◽  
Diabetes Management ◽  
Insulin Pump ◽  
Blood Glucose Control ◽  
Glucose Monitoring ◽  
Insulin Pump Therapy

Technology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that in these subjects the use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems are associated with improved glycemic control along with a better quality of life. Literature regarding technologies and type 2 diabetes is relatively lacking, but innovations may have an important role also in the management of these patients. Some studies in adults with type 2 diabetes have shown benefits with the use of CGM in terms of glycemic variability and improved therapeutic adjustments. Clinical trials about CSII and CGM use in type 2 diabetes may have some pitfalls and future studies are needed to assess how these advanced systems could improve clinical outcomes and also ensure cost-effectiveness in this population. In this narrative review, we aim to highlight the most relevant studies on this topic and to focus on the potential role of new technological devices in type 2 diabetes management.

Sign in / Sign up

Export Citation Format

Share Document